BRCA1 and cancer: A major breakthrough in the targeted therapy of BRCA1-mutant cancers was the finding that cells with BRCA1/2 mutations were exquisitely sensitive to poly (ADP-ribose) polymerase (PARP) inhibitors8,9, which was a great utility of SL.